Blog

César Serrano García: mTOR and PI3K inhibitors can be an effective treatment in GIST SDH-deficient

César Serrano García/X

Jan 21, 2025, 15:31

César Serrano García: mTOR and PI3K inhibitors can be an effective treatment in GIST SDH-deficient

César Serrano García, Group Leader of VHIO´s Sarcoma Translational Research Group, shared a post on X:

“mTOR and/or PI3K inhibitors can be an effective treatment in GIST SDH-deficient

Activating mutations in the PI3K/mTOR pathway in relapsed/mts samples
Sustained 55-months response with everolimus
We provide other insights on tumor evolution.”

César Serrano García

Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway

Authors: Carlo María Cicala et al.

César Serrano García

Ana Vivancos cancer Carlo María Cicala Cesar Serrano Claudia Valverde David Gómez-Peregrina Judit Matito Luis Gros Macarena Gonzalez María Quindos OncoDaily Oncology Paula Fernández-Suárez Paula Pérez-Albert Paula Romero-Lozano Stefania Landolfi

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity